1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Siegfried Holding AG

Siegfried Holding AG

SGFEF
Siegfried Holding AGUS flagOther OTC
100.00
USD
- -
- -
4.38BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
10.49
8.15
12.16
18.47
18.91
19.07
20.15
20.39
26.21
29.13
30
30.04
30.34
Basic EPS, GAAP
1.51
1
0.99
0.72
1.03
1.35
1.28
1.47
2.27
3.71
2.66
3.71
3.85
Free Cash Flow per Basic Share
0.44
-1.48
-1.82
-0.29
0.8
1.1
0.09
1.1
0.15
0.64
1.69
-0.28
-0.08
Dividend per Share
0.12
0.15
0.15
0.18
0.2
0.24
0.26
0.28
0.3
0.32
0.34
0.36
0.38
Book Value per Share
9.36
8.18
7.4
8.26
9.05
9.59
11.21
12.22
14.3
16.67
17.27
20.57
23.38
Tangible Book Value per Share
9.88
9.65
12.2
16.77
16.59
16.05
16.52
17.53
15.76
17.89
18.74
21.44
24.27
Basic Weighted Avg Shares
36
39
40
39
40
42
41
41
42
42
42
43
44
Sales/Revenue/Turnover
375
315
481
718
750
794
834
845
1,102
1,230
1,271
1,295
1,328
Operating Margin (%)
9.99
10.8
8.62
6.49
8.24
9.61
6.85
9.4
11.97
18.62
13.27
15.04
16.29
Depreciation Expense
25
25
34
50
49
50
52
55
83
82
81
85
95
Net Income, GAAP
54
39
39
28
41
56
53
61
96
156
113
160
169
Effective Tax Rate (%)
- -
- -
- -
19.66
29.45
19.75
- -
17.78
24.44
28.47
25.06
18.54
19.31
Profit Margin (%)
14.36
12.23
8.14
3.89
5.44
7.09
6.38
7.2
8.67
12.73
8.87
12.36
12.7
Working Capital
199
166
315
344
366
383
288
457
555
627
585
633
524
LT Debt
60
113
215
91
100
110
- -
- -
- -
- -
- -
- -
- -
Total Equity
362
383
493
661
668
679
692
733
688
791
838
980
1,128
Return on Invested Capital (%)
- -
- -
- -
4.9
5.47
7.37
- -
7.94
13.21
20.3
13.9
15.99
15.5
Return on Capital (%)
- -
- -
- -
7.36
9.97
12.24
- -
11.44
17.79
24.82
16.7
20.66
18.3
Return on Common Equity (%)
17.79
11.85
12.84
9.1
12.01
14.85
12.31
12.54
17.26
23.99
15.72
19.78
17.67

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.15%
9.35%
15.07%
Free Cash Flow
82.2%
43.04%
-72.58%
Net Income, GAAP
20.46%
28.02%
5.37%
Sales/Revenue/Turnover
11.58%
9.96%
2.57%
Total Cash Common Dividend
10.92%
7.44%
8.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,271
2024
- -
- -
- -
- -
1,295
2025
- -
- -
- -
- -
1,328

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.66
2024
- -
- -
- -
- -
3.71
2025
- -
- -
- -
- -
3.85

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.34
2024
- -
- -
- -
- -
0.36
2025
- -
- -
- -
- -
0.38

Company Description

APIChat
CEO
Marcel Imwinkelried
Full Time Employees
3,886
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Untere Bruehlstrasse 4 Zofingen Switzerland 4800
IPO Date
Jul 25, 2014
Website
siegfried.ch
Similar Companies
AstraZeneca Pharma India Limited (ASTRAZEN.NS)
Par Drugs and Chemicals Limited (PAR.NS)
Hikma Pharmaceuticals PLC (HKMPY)
Allied Biotech Corporation (1780.TWO)
Zynerba Pharmaceuticals, Inc. (ZYNE)
Morepen Laboratories Limited (MOREPENLAB.NS)
Business
Siegfried Holding AG, founded in 1873 and headquartered in Zofingen, Switzerland, develops and manufactures active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms as a leading contract development and manufacturing organization (CDMO) for the pharmaceutical industry; its core offerings encompass contract development and manufacturing services for drug substances including highly potent APIs and controlled substances, as well as drug products such as tablets, capsules, sterile vials, ampoules, cartridges, and ointments; the company operates 13 production sites across seven countries on three continents, including Switzerland, Germany, France, Malta, Spain, the United States, and China, serving over 500 customers worldwide and supplying approximately 200 FDA-approved APIs. Siegfried conducts business through two primary segments, Drug Substances and Drug Products, targeting small and large pharmaceutical and biotech firms with integrated services from early-phase process development and optimization through commercial-scale production, registration, packaging, and logistics. The company maintains a global workforce exceeding 3,800 employees and emphasizes sustainability, with 87% renewable electricity usage and a 45.7% reduction in absolute carbon emissions since 2020. In July 2024, Siegfried completed the acquisition of a CDMO site in Grafton, Wisconsin, USA, specializing in early-phase development and manufacturing to enhance Drug Substances capabilities and U.S. market presence; later in 2024, it opened a state-of-the-art quality control lab in Minden, Germany, inaugurated cutting-edge laboratories at Siegfried DINAMIQS for cell and gene therapy, and launched a new global R&D center in Evionnaz, Switzerland; in October 2024, the company unveiled its updated EVOLVE + strategy, prioritizing commercial, development, and operational excellence alongside value-accretive mergers and acquisitions. Siegfried Holding AG trades on the SIX Swiss Exchange under the ticker SFZN (OTC: SGFEF) with a market capitalization of approximately CHF 3.6 billion as of December 2023.

Company News

APIChat

  • businesswire.com

    SK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG

  • seekingalpha.com

    Siegfried Holding AG (SGFEF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Siegfried Holding AG (SGFEF) M&A Call Transcript

  • defenseworld.net

    Siegfried (OTCMKTS:SGFEF) and Jupiter Wellness (NASDAQ:JUPW) Head to Head Survey